On 03 de nov. de 2025, BNTX reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 44.42% surprise. Revenue reached 1.52 bilhão, compared to an expected 979.55 milhão, with a 55.06% difference. The market reacted with a +0.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analistas forecast an EPS of -0.01 USD, with revenue projected to reach 818.49 milhão USD, implying an diminuir of -91.67% EPS, and diminuir of -46.11% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were BioNTech SE - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, BioNTech SE - ADR reported EPS of -$0.12, beating estimates by 44.42%, and revenue of $1.52B, 55.06% above expectations.
How did the market react to BioNTech SE - ADR's Q3 2025 earnings?
The stock price moved up 0.04%, changed from $103.91 before the earnings release to $103.95 the day after.
When is BioNTech SE - ADR expected to report next?
The next earning report is scheduled for 10 de mar. de 2026.
What are the forecasts for BioNTech SE - ADR's next earnings report?
Based on 18
analistas, BioNTech SE - ADR is expected to report EPS of -$0.01 and revenue of $818.49M for Q4 2025.